Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer
- Study type
- Review article
- Design
- Narrative review article (no trial or primary statistical analysis)
- Source
- CA A Cancer J Clinicians · 2025
In plain words
High-grade serous ovarian cancer is the most common and most aggressive type of ovarian cancer. Because it usually causes no symptoms in its early stages, it is often found at an advanced stage, and its treatment includes surgery, chemotherapy and maintenance treatment. This review article explains that understanding the molecular features of the tumour can help with targeted, personalised treatments. The authors stress that the patient's own views and circumstances should play a central role in treatment decisions.
Key results
Study population
This is a review article and no specific patients were enrolled. The subject of the review is high-grade serous ovarian cancer (HGSOC).
Endpoints
This is a review article and has no predefined endpoint. The review covers the aetiology, epidemiology, classification, pathogenesis and the range of current treatment strategies for HGSOC, and also examines the importance of the tumour microenvironment.
Safety and side effects
This is a review article, and no data on the adverse effects of a specific intervention are reported in the abstract.
Clinical significance and place in guidelines
This is a review article and, based on the abstract, it does not report the results of a new trial or a specific change in guidelines. Its main message is the importance of understanding the molecular features of HGSOC (such as homologous recombination deficiency), personalised multimodal treatment in centralised treatment centres, and patient-centred shared decision-making. For specific treatment recommendations, reliable and up-to-date clinical guidelines should be consulted.
Limitations
The abstract is a narrative review and does not describe the literature search method, study selection criteria or assessment of the quality of the evidence. Treatment details and quantitative data are in the full text of the paper. Some authors reported financial relationships with pharmaceutical companies.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.